

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

PT. PFIZER INDONESIA
Local Product Document

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA

1. NAME OF THE MEDICINAL PRODUCT

BeneFIX 250 IU powder and solvent for solution for injection
BeneFIX 500 IU powder and solvent for solution for injection
BeneFIX 1000 IU powder and solvent for solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients, active moieties

Nonacog alfa (INN) (recombinant coagulation factor IX).

Physical Characteristics

BeneFIX is formulated as a sterile, nonpyrogenic, lyophilized powder preparation. It is a clear, colorless solution after reconstitution.

Each single-use vial contains nominally 250, 500, or 1000 international units (IU).

3. PHARMACEUTICAL FORM

Powder for reconstitution and intravenous (IV) injection

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

BeneFIX is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings.

4.2. Posology and method of administration

Dosage

Treatment should be initiated under the supervision of a physician experienced in the treatment of hemophilia B.

Treatment with all factor IX products, including BeneFIX, requires individualized dosage adjustment. The dosage and duration of treatment for all factor IX products depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient's clinical condition. Dosing of BeneFIX may differ from that of plasma-derived factor IX products.

To ensure that the desired factor IX activity level has been achieved, precise monitoring using the factor IX activity assay is advised, in particular for surgical interventions. In order to adjust the dose as appropriate, doses should be titrated taking into consideration factor IX activity, pharmacokinetic parameters (such as half-life and recovery) as well as the clinical situation.

The number of units of factor IX administered is expressed in IU, which are related to the current WHO standard for factor IX products. Factor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an international standard for factor IX in plasma). One IU of factor IX activity is equivalent to that quantity of factor IX in one mL of normal human plasma. Pharmacokinetics have to be assessed regularly in each patient and dosing has to be

Generic Name: Nonacog alfa
 Trade Name: BeneFIX®
 CDS Effective Date: December 22, 2017
 Supersedes: NA
 Approved by BPOM:

adjusted accordingly.

Text for calculating dosage is as follows:

Patients ≥ 15 years

In patients ≥ 15 years, on average, one IU of BeneFIX per kilogram of body weight increased the circulating activity of factor IX by 0.8 ± 0.2 (range 0.4 to 1.4) IU/dL. The method of dose estimation is illustrated in the following example. If you use 0.8 IU/dL average increase of factor IX per IU/kg body weight administered, then:

number of factor IX IU required (IU)	=	Body weight (kg)	X	desired factor IX increase (% or IU/dL)	X	1.2 (IU/kg per IU/dL)*
--------------------------------------	---	------------------	---	---	---	------------------------

* Reciprocal of observed recovery (IU/kg per IU/dL)

Patients < 15 years

In patients < 15 years, on average, one IU of BeneFIX per kilogram of body weight increased the circulating activity of factor IX by 0.7 ± 0.3 (range 0.2 to 2.1 IU/dL; median of 0.6 IU/dL per IU/kg). The method of dose estimation is illustrated in the following example. If you use 0.7 IU/dL average increase of factor IX per IU/kg body weight administered, then:

number of factor IX IU required (IU)	=	Body weight (kg)	X	desired factor IX increase (% or IU/dL)	X	1.4 (IU/kg per IU/dL)*
--------------------------------------	---	------------------	---	---	---	------------------------

* Reciprocal of observed recovery (IU/kg per IU/dL)

Dosage for bleeding episodes and surgery

In the case of the hemorrhagic events listed in the table 1 below, the factor IX activity should not fall below the given plasma activity level (in % of normal or IU/dL) in the corresponding period.

Table 1: Dosing Guide for Control and Prevention of Bleeding Episodes and Surgery

Type of Hemorrhage	Circulating Factor IX Activity Required (% or IU/dL)	Dosing Interval (hours)	Duration of Therapy (days)
Minor			
Uncomplicated hemarthroses, superficial muscle, or soft tissue	20-30	12-24	1-2
Moderate			
Intramuscular or soft tissue with dissection, mucous membranes, dental extractions, or hematuria	25-50	12-24	Treat until bleeding stops and healing begins; about 2 to 7 days
Major			
Pharynx, retropharynx, retroperitoneum, CNS, surgery	50-100	12-24	7-10

Adapted from: Roberts and Eberst

Dosage for prophylaxis

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

In a clinical study for routine secondary prophylaxis the average dose for previously treated adult patients (PTP) was 40 IU/kg (range 13 to 78 IU/kg) at intervals of 3 or 4 days. In younger patients, shorter dosage intervals or higher doses may be necessary.


Elderly population

Clinical studies of BeneFIX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. As with any patient receiving BeneFIX, dose selection for an elderly patient should be individualized.


Administration

BeneFIX is administered intravenously after reconstitution of the lyophilized powder for solution for injection with the supplied diluent. See also section 6.6. It should be injected over several minutes. The rate of administration should be determined by the patient's comfort level.

1. Attach the syringe to the luer end of the infusion set tubing provided.
2. Apply a tourniquet and prepare the injection site by wiping the skin well with an alcohol swab provided in the kit.



3. Perform venipuncture. Insert the needle on the infusion set tubing into the vein, and remove the tourniquet. The reconstituted BeneFIX product should be injected intravenously over several minutes. The rate of administration should be determined by the patient's comfort level.



Reconstituted BeneFIX should not be administered in the same tubing or container with other medicinal products.

Following completion of BeneFIX treatment, remove the infusion set and discard (see also section 6.6).

The safety and efficacy of administration by continuous infusion have not been established. See also sections 4.4 and 4.8.

BeneFIX should be administered using the infusion set provided in the kit, and the pre-filled diluent syringe provided or a single, sterile, disposable plastic syringe. In addition, the solution should be withdrawn from the vial using the vial adapter.

The reconstituted solution may be stored at room temperature prior to administration. However, BeneFIX should be administered within 3 hours after reconstitution.

Note: Agglutination of red blood cells in the tubing/syringe has been reported with the administration of BeneFIX. No adverse events have been reported in association with this observation. To minimize the possibility of agglutination, it is important to limit the amount of blood entering the tubing. Blood should not enter the syringe. If red blood cell agglutination is observed in the tubing or syringe, discard all material (tubing, syringe and BeneFIX solution) and resume administration with a new

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

package.

If any suspected hypersensitivity reaction takes place that is thought to be related to the administration of BeneFIX, the rate of infusion should be decreased or the infusion stopped (see sections 4.4 and 4.8).

Reconstitution


Always wash your hands before performing the following procedures. Aseptic technique (meaning clean and germ-free) should be used during the reconstitution procedure. All components used in the reconstitution and administration of this product should be used as soon as possible after opening their sterile containers to minimize unnecessary exposure to the atmosphere.

BeneFIX is administered by IV infusion after reconstitution with the supplied diluent (0.234% sodium chloride diluent) in the pre-filled syringe.

1. Allow the vial of lyophilized BeneFIX and the pre-filled diluent syringe to reach room temperature.
2. Remove the plastic flip-top cap from the BeneFIX vial to expose the central portions of the rubber stopper.



3. Wipe the top of the vial with the alcohol swab provided, or use another antiseptic solution, and allow to dry. After cleaning, do not touch the rubber stopper with your hand or allow it to touch any surface.
4. Peel back the cover from the clear plastic vial adapter package. Do not remove the adapter from the package.
5. Place the vial on a flat surface. While holding the adapter in the package, place the vial adapter over the vial. Press down firmly on the package until the adapter snaps into place on the top of the vial, with the adapter spike penetrating the vial stopper. Leave the adapter package in place.




6. Grasp the plunger rod as shown in the diagram. Avoid contact with the shaft of the plunger rod. Attach the threaded end of the plunger rod to the diluent syringe plunger by pushing and turning firmly.

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:




7. Remove the tamper-resistant, plastic-tip cap from the diluent syringe by bending the cap up and down to break the perforation. Do not touch the inside of the cap or the syringe tip. Place the cap on its side on a clean surface in a spot where it would be least likely to become environmentally contaminated.




8. Lift the package away from the adapter and discard the package.



9. Place the vial on a flat surface. Connect the diluent syringe to the vial adapter by inserting the tip into the adapter opening while firmly pushing and turning the syringe clockwise until the connection is secured.



10. Slowly depress the plunger rod to inject all the diluent into the BeneFIX vial.



11. Without removing the syringe, gently swirl the contents of the vial until the powder is dissolved.
12. Inspect the final solution for specks before administration. The solution should appear clear


Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

and colorless.

Note: If you use more than one vial of BeneFIX per infusion, reconstitute each vial by following the previous instructions.

13. Ensuring that the syringe plunger rod is still fully depressed, invert the vial. Slowly draw the solution into the syringe.

Note: If you prepared more than one vial of BeneFIX, remove the diluent syringe from the vial adapter, leaving the vial adapter attached to the vial. Quickly attach a separate large luer lock syringe and draw back the reconstituted contents as instructed above. Repeat this procedure with each vial in turn. Do not detach the diluent syringes or the large luer lock syringe until you are ready to attach the large luer lock syringe to the next vial adapter.



14. Detach the syringe from the vial adapter by gently pulling and turning the syringe counterclockwise. Discard the vial with the adapter attached.

Note: If the solution is not to be used immediately, the syringe cap should be carefully replaced. Do not touch the syringe tip or the inside of the cap.

BeneFIX should be administered within 3 hours after reconstitution. The reconstituted solution may be stored at room temperature prior to administration.

4.3. Contraindications

BeneFIX may be contraindicated in patients with a known history of hypersensitivity to any of the constituents of the preparation or in patients with a known history of hypersensitivity to hamster proteins.

4.4. Special warnings and precautions for use

Hypersensitivity

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products, including BeneFIX. Frequently, these events have occurred in close temporal association with the development of factor IX inhibitors. Patients should be informed of the early symptoms and signs of hypersensitivity reactions, including hives, generalized urticaria, chills (rigors), flushing, angioedema, chest tightness, laryngospasm, bronchospasm, dyspnea, wheezing, faintness, hypotension, tachycardia, blurred vision, and anaphylaxis. If allergic or anaphylactic reactions occur, administration of BeneFIX should be stopped immediately, and appropriate medical management should be given, which may include treatment for shock. Patients should be advised to discontinue use of the product and contact their physician and/or seek immediate emergency care, depending on the type/severity of the reaction, if any of these symptoms occur.

Nephrotic syndrome has been reported following immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of allergic reactions to factor IX. The safety and efficacy of using BeneFIX for immune tolerance induction have not been established.

In case of severe allergic reactions, alternative hemostatic measures should be considered.

Activity-neutralizing antibodies (inhibitors)

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

Inhibitors have been detected in patients receiving factor IX-containing products. As with all factor IX products, patients using BeneFIX should be monitored for the development of factor IX inhibitors. Patients with factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with factor IX. Patients experiencing allergic reactions should be evaluated for the presence of inhibitor. Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient's factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions. Patients known to have major deletion mutations of the factor IX gene should be observed closely for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product. In view of the potential for allergic reactions with factor IX concentrates, the initial administrations (approximately 10-20) of factor IX should be performed under medical supervision where proper medical care for allergic reactions could be provided.

Thrombosis

Historically, the administration of factor IX complex concentrates derived from human plasma, containing factors II, VII, IX and X, has been associated with the development of thromboembolic complications. Although BeneFIX contains no coagulation factor other than factor IX, the potential risk of thrombosis and DIC observed with other products containing factor IX should be recognized. Because of the potential risk of thromboembolic complications, caution should be exercised when administering this product to patients with liver disease, to patients post-operatively, to neonates, or to patients at risk of thromboembolic phenomena or DIC.

The safety and efficacy of BeneFIX administration by continuous infusion have not been established. See sections 4.2 and 4.8. There have been post-marketing reports of thrombotic events, including life-threatening superior vena cava (SVC) syndrome in critically ill neonates, while receiving continuous-infusion BeneFIX through a central venous catheter.

In each of these situations, the benefit of treatment with BeneFIX should be weighed against the risk of these complications.

Nephrotic syndrome

Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reaction. The safety and efficacy of using BeneFIX for immune tolerance induction has not been established.

Cardiovascular events

In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk.

4.5. Interaction with other medicinal products and other forms of interaction

No interactions of recombinant coagulation factor IX products with other medicinal products are known.

Temporary correction of abnormal partial thromboplastin time (PTT) was observed; no effect on normal PTT was seen.

4.6. Fertility, pregnancy and lactation

Pregnancy

Animal reproduction and lactation studies have not been conducted with BeneFIX. There is insufficient experience with the use of factor IX products in pregnant women. Therefore, factor IX should be administered to pregnant women only if clearly indicated.

Generic Name: Nonacog alfa
 Trade Name: BeneFIX®
 CDS Effective Date: December 22, 2017
 Supersedes: NA
 Approved by BPOM:

Lactation

There is insufficient experience with the use of factor IX products in lactating women. Therefore, factor IX should be administered to lactating women only if clearly indicated.

4.7. Effects on ability to drive and use machines

On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions BeneFIX has no or negligible influence on the ability to drive or use machines.

4.8. Undesirable effects

Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed and may in some cases progress to severe anaphylaxis (including shock). In some cases, these reactions have progressed to severe anaphylaxis, and they have occurred in close temporal association with development of factor IX inhibitors (see also section 4.4). Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reaction.

Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.

Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.

There is a potential risk of thromboembolic episodes following the administration of factor IX products, see section 4.4.

Tabulated list of adverse reactions

The table below lists adverse reactions reported in the clinical trials of previously treated patients and previously untreated patients and identified in post-marketing use. The frequencies are based on all causality treatment emergent events in pooled clinical trials with 287 subjects.

Table 2: Adverse Reactions Table

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1 000 to <1/100	Frequency not known (cannot be estimated from available data)
Infections and infestations			Infusion-site cellulitis ^k	
Blood and lymphatic system		Factor IX inhibition ^c		
Immune system disorders		Hypersensitivity ^d		Anaphylactic reaction ^o
Nervous system disorders	Headache ^a	Dizziness; dysgeusia	Somnolence; tremor	

Generic Name: Nonacog alfa
 Trade Name: BeneFIX®
 CDS Effective Date: December 22, 2017
 Supersedes: NA
 Approved by BPOM:

Table 2: Adverse Reactions Table

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1 000 to <1/100	Frequency not known (cannot be estimated from available data)
Eye disorders			Visual impairment ^l	
Cardiac disorders			Tachycardia ^m	
Vascular disorders		Phlebitis; hypotension ^e ; flushing ^f		Superior vena cava syndrome ^{o,p} ; deep vein thrombosis ^o ; thrombosis ^o ; thrombophlebitis ^o
Respiratory, thoracic and mediastinal disorders	Cough ^b		Respiratory distress	
Gastrointestinal disorders	Vomiting	Nausea		
Skin and subcutaneous disorders		Rash ^g ; urticaria		
Renal and urinary disorders			Renal infarct ⁿ	
General disorders and administration site conditions	Pyrexia	Chest discomfort ^h ; infusion-site reaction ^j ; infusion-site pain ⁱ	Chills	Inadequate therapeutic response ^o
Investigations				Inadequate factor IX recovery ^{o,q}

^a including migraine, sinus headache
^b including productive cough
^c low-titer transient inhibitor formation and high-titer inhibitor formation
^d including drug hypersensitivity, angioedema, bronchospasm, wheezing, dyspnoea, and laryngospasm
^e including blood pressure decreased
^f including hot flush, feeling hot, skin warm
^g including rash macular, rash papular, rash maculopapular
^h including chest pain and chest tightness
ⁱ including infusion-site pruritus, infusion-site erythema
^j including injection site pain, infusion-site discomfort
^k including cellulitis
^l including scintillating scotoma and blurred vision
^m including heart rate increased, sinus tachycardia
ⁿ developed in a hepatitis C antibody-positive patient 12 days after a dose of BeneFIX for a bleeding episode.
^o ADR identified in post-marketing
^p superior vena cava (SVC) syndrome in critically ill neonates, while receiving continuous-infusion of BeneFIX through a central venous catheter
^q This is a verbatim term. No MedDRA 17.1 PT was retrieved.

Hypersensitivity/allergic reactions

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

If any suspected hypersensitivity reaction takes place that is thought to be related to the administration of BeneFIX see sections 4.2 and 4.4.

Inhibitor development

Patients with hemophilia B may develop neutralizing antibodies (inhibitors).

A clinically relevant, low-responding transient inhibitor (maximum titer 1.5 BU) was detected in 1 out of 65 BeneFIX patients (including 9 patients participating only in the surgery study) who had previously received plasma-derived products (PTPs). This patient was able to continue treatment with BeneFIX with no anamnestic rise in inhibitor or anaphylaxis.

From results of the PUP study, 2/63 patients developed inhibitors after 7 and 15 exposure days. Both were high-titer inhibitors. Both patients experienced allergic manifestations in temporal association with their inhibitor development.

Paediatric population

Allergic reactions might be experienced more frequently in children than in adults.

There are insufficient data to provide information on inhibitor incidence in PUPs (see also section 5.1).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Pusat Farmakovigilans/MESO Nasional

Direktorat Pengawasan Keamanan, Mutu, dan Ekspor Impor Obat, Narkotika, Psikotropika, Prekursor dan Zat Adiktif

Badan Pengawas Obat dan Makanan

Jl. Percetakan Negara No. 23, Jakarta Pusat, 10560

Email: pv-center@pom.go.id

Phone: +62-21-4244691 Ext.1079

Website: <https://e-meso.pom.go.id/ADR>

PT Pfizer Indonesia

Email: IDN.AEReporting@pfizer.com

Website: www.pfizersafetyreporting.com

4.9. Overdose

No symptoms of overdose have been reported with recombinant coagulation factor IX products.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Antihemorrhagic Blood Coagulation Factor IX

ATC Code: B02BD04

Mechanism of action

BeneFIX contains recombinant coagulation factor IX, (nonacog alfa). Recombinant coagulation factor IX is a single chain glycoprotein with an approximate molecular mass of 55,000 Daltons that is a member of the serine protease family of vitamin K-dependent coagulation factors. Recombinant coagulation factor IX is a recombinant DNA-based protein therapeutic, which has structural and

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

functional characteristics comparable to endogenous factor IX. Factor IX is activated by factor VII/tissue factor complex in the extrinsic pathway as well as factor XIa in the intrinsic coagulation pathway activate factor IX. Activated factor IX, in combination with activated factor VIII, activates factor X. This results ultimately in the conversion of prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Factor IX activity is absent or greatly reduced in patients with hemophilia B and substitution therapy may be required.

Hemophilia B is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor IX is increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Clinical trials data on efficacy

Text below is from studies using Previous Formulation BeneFIX and is also applicable to Reformulated BeneFIX.

In 4 clinical studies of BeneFIX, a total of 128 subjects (56 previously treated patients [PTPs], 9 subjects participating only in the surgical study, and 63 previously untreated patients [PUPs]) received more than 28 million IU administered over a period of up to 64 months. The studies included 121 HIV-negative and 7 HIV-positive subjects.

Fifty-six PTPs received approximately 20.9 million IU of BeneFIX in two clinical studies. The median number of exposure days was 83.5. These PTPs who were treated for bleeding episodes on an on-demand basis or for the prevention of bleeds were followed over a median interval of 24 months (range 1 to 29 months; mean 23.4 ± 5.34 months). Fifty-five of these PTPs received a median of 42.8 IU/kg (range 6.5 to 224.6 IU/kg; mean 46.6 ± 23.5 IU/kg) per infusion for bleeding episodes. All subjects were evaluable for efficacy. One subject discontinued the study after one month of treatment due to bleeding episodes that were difficult to control; he did not have a detectable inhibitor. The subject's dose had not been adequately titrated. The remaining 55 subjects were treated successfully. Bleeding episodes that were managed successfully included hemarthroses and bleeding in soft tissue and muscle. Data concerning the severity of bleeding episodes were not reported. Eighty-eight percent of the total infusions administered for bleeding episodes were rated as providing an "excellent" or "good" response. Eighty-one percent of all bleeding episodes were managed with a single infusion of BeneFIX. One subject developed a low-titer, transient inhibitor (maximum titer 1.5 BU). This subject had previously received plasma-derived products without a history of inhibitor development. He was able to continue treatment with BeneFIX with no anamnestic rise in inhibitor or anaphylaxis; however, increased frequency of BeneFIX administration was required; subsequently, the subject's factor IX inhibitor and its effect on the half-life of BeneFIX resolved.

Forty-one of the subjects had measurements of fibrinopeptide A and prothrombin fragment 1 + 2 prior to infusion, 4 to 8 hours and then 24 hours following the infusion. Twenty-nine of the subjects had elevations in fibrinopeptide A with a maximum value of 35.3 nmol/L (22 of the 29 subjects had elevated baseline values). Ten of the subjects had elevated prothrombin fragment 1 + 2 with a maximum value of 1.82 nmol/L (3 of the 10 subjects had elevated baseline values).

Prophylaxis

A total of 20 PTPs were treated with BeneFIX for secondary prophylaxis (the regular administration of FIX replacement therapy to prevent bleeding in patients who may have already demonstrated clinical evidence of hemophilic arthropathy or joint disease) at some regular interval during the study with a mean of 2.0 infusions per week. Nineteen subjects were administered BeneFIX for routine secondary prophylaxis (at least twice weekly) for a total of 345 patient-months with a median follow-

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

up period of 24 months per subject. The average dose used by these 19 subjects was 40.3 IU/kg, ranging from 13 to 78 IU/kg. One additional subject was treated weekly, using an average dose of 33.3 IU/kg, over a period of 21 months. Ninety-three percent of the responses were rated as “excellent” or “effective”. These 20 PTPs received a total of 2,985 infusions of BeneFIX for routine prophylaxis. Seven of these PTPs experienced a total of 26 spontaneous bleeding episodes within 48 hours after an infusion.

Once-weekly 100 IU/kg dosing regimen

In an open-label study of 25 patients (range 12-54 years) comparing on-demand treatment versus prophylaxis when administered at a dose of 100 IU/kg once weekly for approximately 52 weeks, the annualised bleed rate (ABR) for the prophylaxis period was significantly lower ($p < 0.0001$) than the ABR for the on-demand period (mean: 3.6 ± 4.6 , median: 2.0, min-max: 0.0 - 13.8 versus mean: 32.9 ± 17.4 , median: 33.6, min-max: 6.1 - 69.0, respectively). In an open-label crossover study in patients aged 6-64 years, of 100 IU/kg once-weekly (44 patients) and 50 IU/kg twice-weekly (43 patients) with 4-month prophylaxis treatment periods, the ABR for the 100 IU/kg once-weekly prophylaxis period was mean 4.4 ± 10.0 (median 0.0) and mean 2.8 ± 5.7 (median 0.0) for the 50 IU/kg twice-weekly prophylaxis period.

Management of hemostasis was evaluated in the surgical setting. Thirty-six surgical procedures have been performed in 28 subjects. Thirteen (13) minor surgical procedures were performed in 12 subjects, including 7 dental procedures, 1 punch biopsy of the skin, 1 cyst removal, 1 male sterilization, 1 nevus ablation, and 2 ingrown toenail removals. Twenty-three (23) major surgical procedures were performed in 19 subjects, including a liver transplant, splenectomy, 3 inguinal hernia repairs, 11 orthopedic procedures, a calf-debridement and 6 complicated dental extractions.

Twenty-three (23) subjects underwent 27 surgical procedures with a pulse-replacement regimen. The mean perioperative (preoperative and intraoperative) dose for these procedures was 85 ± 32.8 IU/kg (range 25-154.9 IU/kg). The mean total post-operative (inpatient and outpatient) dose was 63.1 ± 22.0 IU/kg (range 28.6-129.0).

Total BeneFIX coverage during the surgical period for the major procedures ranged from 4,230 to 385,800 IU. The pre-operative dose for the major procedures ranged from 75 to 155 IU/kg. Nine of the major surgical procedures were performed in 8 subjects using a continuous infusion regimen. Following pre-operative bolus doses (94.1 -144.5 IU/kg), continuous infusion of BeneFIX was administered at a median rate of 6.7 IU/kg/hr (range of average rates: 4.3-8.6 IU/kg/hr; mean 6.4 ± 1.5 IU/kg/hr) for a median duration of 5 days (range 1-11 days; mean 4.9 ± 3.1). Six of the 8 subjects who had received continuous infusion of BeneFIX in conjunction with major surgeries were switched over to intermittent pulse regimens at a median dose of 56.3 IU/kg (range 33.6-89.1 IU/kg; mean 57.8 ± 18.1 IU/kg SD) for a median of 3.5 exposure days (range 1-5 days, mean 3.3 ± 1.4 SD) during the post-operative period. Although circulating factor IX levels targeted to restore and maintain hemostasis were achieved with both pulse replacement and continuous infusion regimens, clinical trial experience with continuous infusion of BeneFIX for surgical prophylaxis in hemophilia B has been too limited to establish the safety and clinical efficacy of administration of the product by continuous infusion. Subjects administered BeneFIX by continuous infusion for surgical prophylaxis also received intermittent bolus infusions of the product.

Among the surgery subjects, the median increase in circulating factor IX activity was 0.7 IU/dL per IU/kg infused (range 0.3-1.2 IU/dL; mean 0.8 ± 0.2 IU/dL per IU/kg). The median elimination half-life for the surgery subjects was 19.4 hours (range 10-37 hours; mean 21.3 ± 8.1 hours).

Hemostasis was maintained throughout the surgical period; however, one subject required evacuation of a surgical wound site hematoma, and another subject who received BeneFIX after a tooth

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

extraction required further surgical intervention due to oozing at the extraction site. There was no clinical evidence of thrombotic complications in any of the subjects. In seven subjects for whom fibrinopeptide A and prothrombin fragment 1 + 2 were measured pre-infusion, at 4 to 8 hours, and then daily up to 96 hours, there was no evidence of significant increase in coagulation activation. Data from two other subjects were judged to be not evaluable.

Sixty-three PUPs received approximately 6.2 million IU of BeneFIX in an open-label safety and efficacy study over 89 median exposure days. These PUPs were followed over a median interval of 37 months (range 4 to 64 months; mean 38.1 ± 16.4 months). Fifty-four of these PUPs received a median dose of 62.7 IU/kg (range 8.2 to 292.0 IU/kg; mean 75.6 ± 42.5 IU/kg) per infusion for bleeding episodes. Data concerning the severity of bleeding episodes were not reported. Ninety-four percent of the infusions administered to initiate treatment of bleeding were rated as providing “excellent” or “good” response.

Seventy-five percent of all bleeding episodes were managed with a single infusion of BeneFIX. Three of these 54 subjects were not successfully treated, including one episode in a subject due to delayed time to infusion and insufficient dosing, and in 2 subjects due to inhibitor formation. One subject developed a high-titer inhibitor (maximum titer 42 BU) on exposure day 7. A second subject developed a high-titer inhibitor (maximum titer 18 BU) after 15 exposure days. Both subjects experienced allergic manifestations in temporal association with their inhibitor development.

Thirty-two PUPs administered BeneFIX for routine prophylaxis. Twenty-four PUPs administered BeneFIX at least twice weekly for a total of 2,587 infusions. The mean dose per infusion was 72.5 ± 37.1 IU/kg, and the mean duration of prophylaxis was 13.4 ± 8.2 months. Eight PUPs administered BeneFIX once weekly for a total of 571 infusions. The mean dose per infusion was 75.9 ± 17.9 IU/kg, and the mean duration of prophylaxis was 17.6 ± 7.4 months. Five PUPs experienced a total of 6 spontaneous bleeding episodes within 48 hours after an infusion.

Twenty-three PUPs received BeneFIX for surgical prophylaxis in 30 surgical procedures. All surgical procedures were minor, except 2 hernia repairs. The preoperative bolus dose ranged from 32.3 IU/kg to 247.2 IU/kg. The perioperative total dose ranged from 385 to 23,280 IU. Five of the surgical procedures were performed using a continuous infusion regimen over 3 to 5 days. Clinical trial experience with continuous infusion of BeneFIX for surgical prophylaxis in hemophilia B has been too limited to establish the safety and clinical efficacy of administration of the product by continuous infusion.

Pediatric population

Safety and efficacy have been demonstrated in previously treated and previously untreated pediatric patients. See also section 4.2.

For dosing information regarding use in children, see section 4.2.

5.2. Pharmacokinetic properties

A single infusion of BeneFIX in patients (baseline data) with hemophilia B has shown mean \pm SD recovery values, determined by age, 0.78 ± 0.23 IU/dL/IU/kg (range 0.4 to 1.4 IU/dL per IU/kg) for those ≥ 15 years old (n=37), and 0.68 ± 0.30 IU/dL per IU/kg (range 0.18 to 2.08 IU/dL per IU/kg) for those < 15 years old (n=56).

In a randomized, cross-over pharmacokinetic study, BeneFIX reconstituted in 0.234% sodium chloride diluent was shown to be pharmacokinetically equivalent to the previously marketed BeneFIX (reconstituted with Sterile Water for Injection) in 24 PTP patients (≥ 12 years) at a dose of 75 IU/kg. In addition, pharmacokinetic parameters were followed up in 23 of the same PTP after repeated

Generic Name: Nonacog alfa
 Trade Name: BeneFIX®
 CDS Effective Date: December 22, 2017
 Supersedes: NA
 Approved by BPOM:

administration of BeneFIX for six months and found to be unchanged compared with those obtained at the initial evaluation. A summary of pharmacokinetic data are presented in Table 3:

Table 3: Pharmacokinetic Parameter Estimates for BeneFIX (75 IU/kg) at Baseline and Month 6 in Previously Treated Patients with Hemophilia B		
Parameter	Baseline n = 24 Mean ± SD	Month 6 n = 23 Mean ± SD
C _{max} (IU/dL)	54.5 ± 15.0	57.3 ± 13.2
AUC _∞ (IU·hr/dL)	940 ± 237	923 ± 205
t _{1/2} (hr)	22.4 ± 5.3	23.8 ± 6.5
CL (mL/hr/kg)	8.47 ± 2.12	8.54 ± 2.04
Recovery (IU/dL/IU/kg)	0.73 ± 0.20	0.76 ± 0.18

Abbreviations: AUC_∞ = area under the plasma concentration-time curve from time zero to infinity; C_{max} = peak concentration; t_{1/2} = plasma elimination half-life; CL = clearance; SD = standard deviation.

A single-dose pharmacokinetic study reported a longer estimate of t_{1/2} when sample collection to measure factor IX activity (FIX) was extended to 96 hours. A summary of pharmacokinetic data is presented in Table 4.

Table 4. Pharmacokinetic Parameter Estimates for BeneFIX (50 IU/kg) in Previously Treated Patients with Hemophilia B aged 6 – <12 years and ≥ 18 years.		
Parameter	6 - <12 years n = 4 Mean ± SD	≥18 years n = 8 Mean ± SD
C _{max} (IU/dL)	39.8 ± 9.93	42.8 ± 7.52
AUC _∞ (IU·hr/dL)	791 ± 118	1178 ± 181
t _{1/2} (hr)	27.9 ± 4.49	39.6 ± 7.38
CL (mL/hr/kg)	6.44 ± 1.03	4.34 ± 0.655
Recovery (IU/dL per IU/kg)	0.80 ± 0.20	0.83 ± 0.15

Abbreviations: AUC_∞ = area under the plasma concentration-time curve from time zero to infinity; C_{max} = peak concentration; t_{1/2} = plasma elimination half-life; CL = clearance; SD = standard deviation.

5.3. Preclinical safety data

BeneFIX has been shown to be non-mutagenic in the Ames assay and non-clastogenic in a chromosomal aberrations assay. No investigations on carcinogenesis or impairment of fertility have been conducted.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Powder

Sucrose

Glycine

L Histidine

Polysorbate 80

Solvent

Sodium chloride solution

Generic Name: Nonacog alfa
Trade Name: BeneFIX®
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

6.2. Incompatibilities

In the absence of incompatibility studies, reconstituted BeneFIX must not be administered in the same tubing or container with other medicinal products. Only the provided infusion set should be used. Treatment failure can occur as a consequence of human coagulation factor IX adsorption to the internal surfaces of some infusion equipment.

6.3. Shelf life and Special Precaution for Storage

BeneFIX should be stored at 2°C -8 °C, with a single short-term period permitted at room temperature-not exceeding 30 °C - for up to 6 months within this expiry period. The patient should write in the space provided on the outer carton the date the product was placed at room temperature. At the end of the 6-month period, the product should not be put back into the refrigerator, but should be used immediately or discarded.

Freezing should be avoided to prevent damage to the pre-filled diluent syringe. BeneFIX, when reconstituted, contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of BeneFIX, including storage time elapsed in a PVC container following reconstitution. It is important that the recommendations in section 4.2 be followed closely.

6.4. Nature and contents of container

BeneFIX 250 IU, 500 IU, 1000 IU powder and solvent for solution for injection

BeneFIX 250 IU, 500 IU, 1000 IU of powder in a 10 mL vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5 mL of clear, colourless solvent in a pre-filled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.

6.5. Special precautions for disposal and other handling

Reconstitute lyophilized BeneFIX powder for injection with the supplied diluent (0.234% sodium chloride solution) from the pre-filled syringe provided. Once the diluent has been injected into the vial, gently rotate the vial until all powder is dissolved. After reconstitution, the solution is drawn back into the syringe and infused.

The solution should be clear and colorless. The solution should be discarded if visible particulate matter or discoloration is observed. The product does not contain a preservative, and the reconstituted solution should be used within 3 hours after reconstitution.

All unused solution, empty vials and used needles and syringes must be discarded in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Manufactured by:

Wyeth Farma, S.A.
Autovía del Norte A-1 Km 23
Desvío Algete Km 1
28700 San Sebastián de los Reyes
Madrid, Spain

Diluent:

Manufactured by:

Vetter Pharma-Fertigung GmbH & Co.KG, Langenargen, Germany

Generic Name: Nonacog alfa
Trade Name: BeneFIX[®]
CDS Effective Date: December 22, 2017
Supersedes: NA
Approved by BPOM:

Imported by:
PT. Pfizer Indonesia
Jakarta, Indonesia

8. MARKETING AUTHORISATION NUMBER(S)

BeneFIX 250 IU; Reg. No.: DKI2158800244A1
BeneFIX 500 IU; Reg. No.: DKI2158800244B1
BeneFIX 1000 IU; Reg. No.: DKI2158800244C1

HARUS DENGAN RESEP DOKTER

9. DATE OF REVISION OF THE TEXT

12/2025

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

Leaflet kemasan: Informasi bagi pengguna

BeneFIX® 250 IU serbuk dan pelarut untuk larutan injeksi
BeneFIX® 500 IU serbuk dan pelarut untuk larutan injeksi
BeneFIX® 1000 IU serbuk dan pelarut untuk larutan injeksi

Nonacog alfa (faktor koagulasi IX rekombinan)

Bacalah leaflet ini dengan teliti sebelum Anda menggunakan obat ini karena berisi informasi yang penting untuk Anda.

- Simpan leaflet ini. Anda mungkin perlu membacanya kembali.
- Jika Anda memiliki pertanyaan lebih lanjut, tanyakan kepada dokter, apoteker, atau perawat Anda.
- Obat ini telah diresepkan hanya untuk Anda. Jangan memberikannya kepada orang lain. Obat ini dapat membahayakan mereka, sekalipun tanda-tanda penyakit mereka sama dengan Anda.
- Jika Anda mengalami efek samping apa pun, konsultasikan dengan dokter, apoteker, atau perawat Anda. Termasuk setiap kemungkinan efek samping yang tidak tercantum dalam leaflet ini. Lihat bagian 13.

Isi leaflet ini

1. Nama obat
2. Bentuk sediaan
3. Deskripsi obat
4. Apa kandungan obat ini?
5. Kekuatan obat
6. Apa kegunaan obat ini?
7. Berapa banyak dan seberapa sering Anda seharusnya menggunakan obat ini? Apa yang harus dilakukan jika ada dosis terlewat?
8. Kapan seharusnya Anda tidak menggunakan obat ini?
9. Apa pertimbangan saat menggunakan obat ini?
10. Apa saja obat lain atau makanan yang harus dihindari selama menggunakan obat ini?
11. Apakah obat tersebut aman bagi ibu hamil dan menyusui?
12. Apakah pasien diizinkan mengemudi dan mengoperasikan mesin saat menggunakan obat ini?
13. Apa saja potensi efek yang tidak diinginkan dari penggunaan obat ini?
14. Tanda-tanda dan gejala-gejala overdosis
15. Apa yang harus dilakukan jika Anda menggunakan lebih dari dosis yang dianjurkan?
16. Bagaimana cara menyimpan obat ini?
17. Nomor otorisasi pemasaran
18. Nama dan alamat pemohon dan/atau pemilik obat sesuai dengan ketentuan yang berlaku
19. Tanggal Revisi PIL
20. Peringatan khusus

1. Nama obat

BeneFIX®

2. Bentuk sediaan

Serbuk dan pelarut untuk larutan injeksi.

3. Deskripsi obat

BeneFIX® diformulasikan sebagai sediaan serbuk steril, nonpirogenik, dan terliofilisasi. Sediaan ini berupa larutan bening dan tidak berwarna setelah rekonstitusi.

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

4. Apa kandungan obat ini?

Zat aktifnya adalah nonacog alfa (faktor koagulasi IX rekombinan). Setiap vial BeneFIX® secara nominal berisi 250, 500, atau 1000 satuan internasional (IU) nonacog alfa.

Daftar eksipien

Serbuk

Sukrosa

Glisin

L Histidin

Polisorbat 80

Pelarut

Larutan natrium klorida

5. Kekuatan obat

Vial sekali pakai: 250, 500, atau 1000 satuan internasional (IU)

6. Apa kegunaan obat ini?

BeneFIX® diindikasikan untuk mengontrol dan mencegah episode perdarahan dan untuk profilaksis rutin dan bedah pada pasien dengan hemofilia B (defisiensi faktor IX bawaan atau penyakit Christmas), termasuk mengontrol dan mencegah perdarahan dalam pembedahan.

7. Berapa banyak dan seberapa sering Anda seharusnya menggunakan obat ini? Apa yang harus dilakukan jika ada dosis terlewat?

Selalu gunakan obat ini dengan tepat sesuai anjuran dokter atau apoteker Anda. Tanyakan kepada dokter atau apoteker jika Anda merasa tidak yakin.

Dokter Anda akan memutuskan dosis BeneFIX® yang akan Anda terima. Dosis dan durasi ini bergantung pada kebutuhan individual Anda untuk menggantikan terapi faktor IX dan seberapa cepat tubuh Anda menghabiskan faktor IX yang akan diperiksa secara teratur. Anda mungkin akan mengamati perbedaan dosis yang Anda terima jika Anda beralih dari produk faktor IX yang berasal dari plasma ke BeneFIX®.

Dokter Anda mungkin memutuskan untuk mengubah dosis BeneFIX® yang Anda terima selama pengobatan.

Rekonstitusi dan pemberian

Prosedur di bawah ini diberikan sebagai panduan untuk rekonstitusi dan pemberian BeneFIX®. Pasien harus mematuhi prosedur pungsi vena spesifik yang disediakan oleh dokter mereka.

BeneFIX® diberikan melalui infus intravena setelah rekonstitusi dengan pelarut yang disediakan (pelarut natrium klorida 0,234%) dalam alat suntik pre-filled.

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:


Cuci selalu kedua tangan Anda sebelum melakukan prosedur ini. Teknik aseptik (yang berarti bersih dan bebas kuman) harus diterapkan selama prosedur rekonstitusi. Semua komponen yang digunakan dalam rekonstitusi dan pemberian produk ini harus digunakan sesegera mungkin setelah membuka wadah sterilnya untuk meminimalkan paparan yang tidak perlu terhadap atmosfer.

Rekonstitusi:

1. Biarkan vial BeneFIX® terliofilisasi dan alat suntik pelarut pre-filled mencapai suhu ruang terlebih dahulu.
2. Lepaskan sungkup plastik flip-top dari vial BeneFIX® hingga memperlihatkan bagian tengah sumbat karet.



3. Seka bagian atas vial dengan tisu penyeka alkohol yang tersedia, atau gunakan larutan antiseptik lainnya, dan biarkan hingga mengering. Setelah dibersihkan, jangan menyentuh sumbat karet dengan tangan Anda atau membiarkannya bersinggungan dengan permukaan apa pun.
4. Kelupas penutup dari kemasan adaptor vial plastik bening. **Jangan mengeluarkan adaptor dari kemasannya.**
5. Tempatkan vial di permukaan yang datar. Sambil memegang adaptor di dalam kemasan, tempatkan adaptor vial di atas vial. Tekan kuat-kuat pada kemasan hingga adaptor terpasang pada tempatnya di bagian atas vial, dengan penusuk adaptor menembus sumbat vial. Biarkan kemasan adaptor tetap terpasang.




6. Pegang tangkai piston seperti yang diperlihatkan dalam diagram. Hindari kontak dengan poros tangkai piston. Sambungkan ujung tangkai piston yang berulir ke piston alat suntik pelarut dengan mendorong dan memutarinya dengan kuat.



Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:


7. Lepaskan sungkup ujung plastik yang tahan-perusakan dari alat suntik pelarut dengan membengkokkan sungkup ke atas dan ke bawah untuk menyobek perforasinya. Jangan menyentuh bagian dalam sungkup atau ujung alat suntik. Tempatkan sungkup pada posisi horizontal di atas permukaan yang bersih di tempat yang paling kecil kemungkinan mengalami kontaminasi lingkungan.




8. Lepaskan kemasan dari adaptor dan buang kemasannya.



9. Tempatkan vial di permukaan yang datar. Sambungkan alat suntik pelarut ke adaptor vial dengan memasukkan ujungnya dalam lubang adaptor sambil mendorong dengan kuat dan memutar alat suntik searah jarum jam hingga tersambung dengan kuat.




10. Dorong perlahan tangkai piston untuk menginjeksikan semua pelarut ke dalam vial BeneFIX®.



11. Tanpa melepaskan alat suntik, putar **perlahan** isi vial hingga serbuknya larut.
12. Periksa larutan akhir untuk melihat adanya bintik-bintik sebelum diberikan. Larutan harus terlihat bening dan tidak berwarna.
Catatan: Jika Anda menggunakan lebih dari satu vial BeneFIX® per infus, lakukan rekonstitusi terhadap masing-masing vial dengan mengikuti petunjuk sebelumnya.
13. Dengan memastikan batang piston alat suntik masih ditekan sepenuhnya, balik vial. Tarik larutan perlahan ke dalam alat suntik.
Catatan: Jika Anda menyiapkan lebih dari satu vial BeneFIX®, lepaskan alat suntik pelarut dari adaptor vial, dengan membiarkan adaptor vial tetap terpasang ke vial. Sambungkan dengan cepat alat suntik kunci luer besar terpisah dan tarik kembali isi yang telah direkonstitusi sesuai petunjuk di atas. Ulangi prosedur ini dengan masing-masing vial secara

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

bergiliran. Jangan melepaskan alat suntik pelarut atau alat suntik kunci luer besar hingga Anda siap untuk memasang alat suntik kunci luer besar ke adaptor vial berikutnya.



14. Lepaskan alat suntik dari adaptor vial dengan menarik dan memutar alat suntik perlahan berlawanan dengan arah jarum jam. Buang vial dengan adaptor tetap dalam kondisi terpasang. Catatan: Jika larutan tidak akan digunakan segera, sungkup alat suntik harus dipasang kembali dengan hati-hati. Jangan sentuh ujung alat suntik atau bagian dalam sungkup.

BeneFIX® harus diberikan dalam waktu 3 jam setelah rekonstitusi. Larutan yang telah direkonstitusi dapat disimpan pada suhu ruang sebelum diberikan.


Pemberian

BeneFIX® diberikan secara intravena setelah merekonstitusi serbuk terliofilisasi menggunakan pelarut yang disediakan untuk menghasilkan larutan injeksi. Larutan harus diinjeksikan dalam waktu beberapa menit. Dokter Anda dapat mengubah laju infus yang dianjurkan untuk Anda sehingga membuat proses infus lebih nyaman.

1. Sambungkan alat suntik ke ujung luer slang set infus yang disediakan.
2. Pasang tourniquet dan siapkan lokasi injeksi dengan mengusap kulit menggunakan tisu alkohol yang disediakan di dalam kit.



3. Lakukan prosedur pungsi vena. Suntikkan jarum pada slang set infus ke pembuluh vena, dan lepaskan tourniquet. Produk BeneFIX® yang direkonstitusi harus diinjeksikan secara intravena dalam waktu beberapa menit. Laju pemberian harus ditentukan berdasarkan tingkat kenyamanan pasien.



BeneFIX® yang telah direkonstitusi tidak boleh diberikan melalui slang atau wadah yang sama dengan produk obat lainnya.

Setelah pengobatan BeneFIX® selesai, lepaskan set infus lalu buang.

Karena penggunaan BeneFIX® melalui infus kontinu (drip) masih belum dievaluasi, maka BeneFIX® tidak boleh dicampur dengan larutan infus atau diberikan dalam bentuk drip.

BeneFIX® harus diberikan dengan menggunakan set infus yang disediakan di dalam kit, dan alat suntik pelarut pre-filled atau alat suntik plastik tunggal, steril, dan sekali pakai. Di samping itu, larutan

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

harus ditarik dari vial dengan menggunakan adaptor vial.

Larutan yang telah direkonstitusi dapat disimpan pada suhu ruang sebelum diberikan. Namun demikian, BeneFIX® harus diberikan dalam waktu 3 jam setelah rekonstitusi.

Catatan: Penggumpalan sel darah merah dalam slang/alat suntik telah dilaporkan terjadi saat pemberian BeneFIX®. Tidak ada kejadian merugikan yang dilaporkan terkait dengan pengamatan ini. Untuk meminimalkan kemungkinan aglutinasi, penting kiranya untuk membatasi jumlah darah yang memasuki slang. Darah tidak boleh memasuki alat suntik. Jika aglutinasi sel darah merah teramati di dalam slang atau alat suntik, buang semua material (slang, alat suntik, dan larutan BeneFIX®) dan lanjutkan pemberian menggunakan paket yang baru.

Jika diduga terjadi reaksi hipersensitivitas yang dianggap berkaitan dengan pemberian BeneFIX®, laju infus harus diturunkan atau infus harus dihentikan.

Jika Anda terlewat satu dosis, konsultasikan dengan dokter, apoteker, atau perawat Anda.

8. Kapan seharusnya Anda tidak menggunakan obat ini?

Jangan menggunakan BeneFIX®

- jika Anda alergi terhadap nonacog alfa atau bahan lain dalam obat ini (tercantum dalam bagian 4).
- jika Anda alergi terhadap protein hamster.

9. Apa pertimbangan saat menggunakan obat ini?

- Konsultasikan dengan dokter atau apoteker Anda sebelum menggunakan BeneFIX®.
- Kunjungi dokter Anda segera jika perdarahan Anda tidak berhenti sesuai harapan.
- Reaksi alergi mungkin terjadi. Produk bisa jadi mengandung jejak protein hamster (lihat Jangan menggunakan BeneFIX®). Reaksi anafilaktik yang berpotensi mengancam nyawa (reaksi alergi berat) telah terjadi sehubungan dengan produk faktor IX, termasuk BeneFIX®. Tanda-tanda awal reaksi alergi di antaranya kesulitan bernapas, napas pendek, pembengkakan, kaligata, gatal-gatal, urtikaria generalisata, dada terasa sesak, mengi, tekanan darah rendah, penglihatan kabur, dan anafilaksis (reaksi alergi berat yang dapat menyebabkan kesulitan menelan dan/atau bernapas, wajah dan/atau tangan memerah atau membengkak).
- Jika terjadi reaksi alergi atau reaksi tipe anafilaktik, **hentikan infus segera dan hubungi dokter atau dapatkan pertolongan medis darurat secepatnya**. Jika terjadi reaksi alergi berat, perlu dipertimbangkan terapi alternatif.
- Antibodi netralisasi aktivitas (inhibitor) adalah suatu kejadian yang tidak umum pada pasien yang sebelumnya telah menerima pengobatan dengan produk yang mengandung faktor IX. Namun demikian, seperti halnya semua produk faktor IX, Anda harus dipantau dengan ketat untuk mengamati pembentukan inhibitor faktor IX selama menjalani pengobatan dengan BeneFIX®.
- Riset telah menunjukkan keterkaitan antara kemunculan inhibitor faktor IX dan reaksi alergi. Oleh karena itu, jika Anda mengalami reaksi alergi seperti yang diuraikan di atas, Anda harus dites untuk memastikan keberadaan inhibitor. Perlu diketahui bahwa pasien dengan inhibitor faktor IX lebih berisiko mengalami anafilaksis saat pengobatan dengan BeneFIX® di waktu mendatang.
- Produksi faktor IX di dalam tubuh dikendalikan oleh gen faktor IX. Pasien yang mengalami mutasi spesifik pada gen faktor IX mereka seperti penghapusan besar memiliki kemungkinan lebih besar untuk memunculkan inhibitor terhadap faktor IX dan/atau mengalami reaksi alergi. Oleh karena itu, jika Anda diketahui mengalami mutasi seperti ini, dokter Anda mungkin akan

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

mengawasi Anda lebih ketat untuk melihat tanda-tanda reaksi alergi, khususnya saat Anda memulai penggunaan BeneFIX® untuk pertama kali.

- Dikarenakan adanya risiko reaksi alergi sehubungan dengan faktor IX, pemberian pertama BeneFIX® kepada Anda harus dilakukan di bawah pengawasan medis yang menyediakan perawatan medis yang tepat untuk menangani reaksi alergi.
- Jika Anda menderita penyakit hati atau jantung, atau baru-baru ini menjalani pembedahan, ada peningkatan risiko komplikasi bekuan darah (koagulasi).
- Gangguan ginjal (sindrom nefrotik) telah dilaporkan setelah pemberian dosis tinggi faktor IX yang berasal dari plasma pada pasien hemofilia B dengan penghambat faktor IX dan riwayat reaksi alergi.

10. Apa saja obat lain atau makanan yang harus dihindari selama menggunakan obat ini?

Beri tahu dokter atau apoteker Anda jika Anda sedang, belum lama ini, atau akan menggunakan obat lain.

11. Apakah obat tersebut aman bagi ibu hamil dan menyusui?

Jika Anda sedang hamil atau menyusui, menduga diri Anda sedang hamil, atau berencana untuk hamil, Anda hanya boleh menerima BeneFIX® dengan petunjuk khusus dari dokter Anda. Belum diketahui apakah BeneFIX® dapat membahayakan bagi janin jika diberikan kepada perempuan hamil. Dokter mungkin menyarankan Anda untuk menghentikan pengobatan dengan BeneFIX® jika Anda sedang menyusui atau hamil.

Mintalah saran dari dokter atau apoteker Anda sebelum menggunakan obat ini.

12. Apakah pasien diizinkan mengemudi dan mengoperasikan mesin saat menggunakan obat ini?

Pengaruh BeneFIX® terhadap kemampuan mengemudi atau menjalankan mesin terbilang nihil atau dapat dikesampingkan.

13. Apa saja potensi efek yang tidak diinginkan dari penggunaan obat ini?

Seperti semua obat-obatan yang ada, obat ini bisa menimbulkan efek samping, meskipun tidak semua orang mengalaminya.

Hipersensitivitas/reaksi alergi

Reaksi hipersensitivitas tipe alergi mungkin terjadi dengan pemberian BeneFIX®. Reaksi tersebut meliputi pembengkakan wajah atau tenggorok, rasa panas dan menyengat di lokasi infus, menggigil, pipi memerah, gatal-gatal, sakit kepala, kaligata, tekanan darah rendah, lesu, mual, gelisah, denyut jantung cepat, dada terasa sesak, kesemutan, muntah, mengi. Dalam beberapa kasus, reaksi ini berkembang menjadi anafilaksis berat. Reaksi alergi dapat terjadi bersama dengan munculnya inhibitor faktor IX.

Reaksi ini berpotensi mengancam nyawa. Jika terjadi reaksi alergi atau anafilaktik, **hentikan infus segera dan hubungi dokter atau dapatkan pertolongan medis darurat secepatnya**. Pengobatan yang diperlukan bergantung pada sifat dan tingkat keparahan efek samping.

Kemunculan inhibitor

Pasien dengan hemofilia B bisa jadi memunculkan antibodi netralisasi (inhibitor) terhadap faktor IX. Jika inhibitor tersebut muncul, tandanya dapat berupa peningkatan jumlah BeneFIX® yang umumnya

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

dibutuhkan untuk mengobati perdarahan dan/atau perdarahan yang terus terjadi setelah pengobatan. Dalam kasus seperti ini, disarankan untuk menghubungi pusat khusus hemofilia. Dokter mungkin ingin memantau Anda untuk melihat perkembangan inhibitor.

Gangguan ginjal telah dilaporkan terjadi setelah pemberian dosis tinggi faktor IX yang berasal dari plasma untuk memicu toleransi imun pada pasien hemofilia B dengan penghambat faktor IX dan riwayat reaksi alergi.

Kejadian trombotik

BeneFIX® dapat meningkatkan risiko trombosis (bekuan darah abnormal) pada tubuh Anda jika Anda memiliki faktor risiko yang memunculkan bekuan darah, termasuk kateter vena yang ditanam. Terdapat laporan kejadian bekuan darah yang berat, termasuk bekuan darah yang mengancam nyawa pada bayi yang kritis, saat menerima infus kontinu BeneFIX® melalui kateter vena sentral. Kasus berupa tromboflebitis perifer (nyeri dan kemerahan pada pembuluh vena) dan trombosis vena dalam (bekuan darah pada anggota gerak) juga pernah dilaporkan; dalam sebagian besar kasus ini, BeneFIX® diberikan melalui infus kontinu, yang bukan merupakan metode pemberian yang disetujui.

Efek samping yang sangat umum (dapat dialami lebih dari 1 di antara 10 orang)

- Sakit kepala
- Batuk
- Muntah
- Demam

Efek samping yang umum (dapat dialami hingga 1 di antara 10 orang)

- Munculnya antibodi netralisasi (inhibitor)
- Hipersensitivitas/reaksi alergi
- Pusing, perubahan indra perasa
- Flebitis (nyeri dan kemerahan pada pembuluh vena), tekanan darah rendah, pipi memerah
- Mual
- Ruam, kaligata
- Dada tidak nyaman (termasuk nyeri dada)
- Reaksi di lokasi infus (termasuk gatal-gatal dan kemerahan di lokasi infus), nyeri di lokasi infus, dan ketidaknyamanan

Efek samping yang tidak umum (dapat dialami hingga 1 di antara 100 orang)

- Selulitis di lokasi infus (nyeri dan kemerahan pada kulit)
- Mengantuk, gemetar
- Gangguan penglihatan (termasuk penglihatan kabur, munculnya bintik-bintik/silau)
- Denyut jantung cepat
- Distres pernapasan
- Infark ginjal (terganggunya pasokan darah ke ginjal)
- Menggigil

Efek samping dengan frekuensi yang tidak diketahui (frekuensinya tidak dapat diperkirakan dari data yang tersedia)

- Reaksi anafilaktik
- Kejadian trombotik (bekuan darah abnormal)
- Kurangnya respons terhadap pengobatan (kegagalan untuk menghentikan atau mencegah episode perdarahan)

Melaporkan efek samping

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

Jika Anda mengalami efek samping apa pun, konsultasikan dengan dokter, apoteker, atau perawat Anda. Termasuk setiap kemungkinan efek samping yang tidak tercantum dalam leaflet ini. Dengan melaporkan efek samping, Anda bisa membantu memberikan informasi lebih lanjut mengenai keamanan obat ini.

Untuk melaporkan efek samping, hubungi www.pfizersafetyreporting.com atau email di IDN.AEReporting@pfizer.com.

14. Tanda-tanda dan gejala-gejala overdosis

Tidak ada gejala overdosis yang dilaporkan terkait dengan produk faktor koagulasi IX rekombinan.

15. Apa yang harus dilakukan jika Anda menggunakan lebih dari dosis yang dianjurkan?

Hubungi dokter Anda segera jika Anda menyuntikkan BeneFIX® melebihi yang dianjurkan oleh dokter Anda.

16. Bagaimana cara menyimpan obat ini?

BeneFIX® harus disimpan pada suhu 2°C–8°C, dengan penempatan pada suhu ruang satu kali untuk jangka pendek pada suhu tidak lebih dari 30°C - hingga 6 bulan dalam periode kedaluwarsa ini. Untuk memudahkan Anda, catat pada kemasan luarnya tanggal ketika BeneFIX® dikeluarkan dari lemari pendingin dan diletakkan pada suhu ruangan. Di akhir periode 6 bulan penyimpanan pada suhu ruang ini, produk tidak boleh dikembalikan ke dalam lemari pendingin, tetapi harus segera digunakan atau dibuang.

Jangan dibekukan.

Jauhkan obat ini dari pandangan dan jangkauan anak-anak.

Jangan menggunakan obat ini jika sudah melewati tanggal kedaluwarsanya.

Gunakan larutan yang direkonstitusi secepatnya atau dalam waktu 3 jam.

17. Nomor otorisasi pemasaran

BeneFIX® 250 IU; Reg. No.: DKI2158800244A1
BeneFIX® 500 IU; Reg. No.: DKI2158800244B1
BeneFIX® 1000 IU; Reg. No.: DKI2158800244C1

18. Nama dan alamat pemohon dan/atau pemilik obat sesuai dengan ketentuan yang berlaku

Diproduksi oleh:

Wyeth Farma, S.A.
Autovía del Norte A-1 Km 23
Desvío Algete Km 1
28700 San Sebastián de los Reyes
Madrid, Spanyol

Pelarut:

Diproduksi oleh:

Vetter Pharma-Fertigung GmbH & Co.KG, Langenargen, Jerman

Nama Generik: Nonacog alfa
Nama Dagang: BeneFIX®
Tanggal Berlaku CDS: 22 Desember 2017
Menggantikan: NA
Disetujui oleh BPOM:

Diimpor oleh:

PT. Pfizer Indonesia
Jakarta, Indonesia

19. Tanggal Revisi PIL

12/2025

20. Peringatan khusus

HARUS DENGAN RESEP DOKTER